Boehringer Ingelheim and Cognizant Launch Innovative Cloud Platform to Expedite Drug Development

In a significant advancement for the biopharmaceutical industry, Boehringer Ingelheim and Cognizant have announced the go-live of an integrated cloud platform aimed at accelerating the development and delivery of innovative therapies. Powered by the Veeva Development Cloud, this system heralds a new era in medicinal development, streamlining previously fragmented processes and enhancing operational efficiencies.

On March 11, 2025, the companies revealed that they have completed Phase One of their collaborative project, which was first introduced in 2023. The initiative, known as the «One Medicine Platform,» consolidates over 20 legacy systems into a unified ecosystem. This strategic move is expected to improve cross-functional collaboration and lead to significant efficiencies across the board.

As the primary system integrator for this ambitious project, Cognizant played a crucial role in developing a comprehensive program roadmap, utilizing agile methodologies, and establishing the implementation workflow. The project encompassed a wide range of services including program management, system architecture and design, training, integration, migration, testing, and validation. Cognizant’s collaboration with Syneos Health Consulting for business process engineering, along with support from Veeva for system architecture and configuration, has further bolstered the platform’s effectiveness.

During the inaugural phase, Cognizant successfully implemented the new platform across various critical functions, including clinical data, clinical operations, regulatory, and quality assurance. This new holistic approach is anticipated to streamline the workflows of more than 15,000 users engaged in Clinical Development programs. Looking ahead, Phase Two of the collaboration aims to deepen improvements in Boehringer Ingelheim’s clinical operations and expand the integration of additional regulatory modules.

According to Oliver Fink, Head of Learning, Processes & Digitalization at Boehringer Ingelheim, «For years, Boehringer Ingelheim used multiple vendor systems which lacked the ability to communicate with each other, leading to complex workflows. The launch of our One Medicine Platform revolutionizes our medicinal development processes and elevates our operational efficiencies to unprecedented levels.»

Gagan Syal, Head of Life Sciences for EMEA & APAC at Cognizant, expressed his enthusiasm about the collaborative success, stating, «We are pleased to achieve this program milestone in our partnership with Boehringer Ingelheim. With this new system, Boehringer Ingelheim will address data challenges and latency issues, ultimately accelerating the time to market for its products. Our close collaboration has enabled us to execute this project in record time.»

The launch of the One Medicine Platform represents a substantial stride forward for Boehringer Ingelheim in its mission to deliver life-transforming treatments more efficiently. As the global biopharmaceutical landscape continues to evolve, such innovations are critical in ensuring that patients gain access to cutting-edge therapies in a timely manner.